首页> 外文期刊>JACC. Cardiovascular imaging. >A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent.
【24h】

A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent.

机译:超声心动图检查是否有超声造影剂的危重住院患者死亡率的回顾性比较。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVES: To compare acute mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (UCA). BACKGROUND: Because of serious cardiopulmonary reactions reported immediately after administration of perflutren-containing UCAs, the FDA required a black box safety warning for this class of agents, including perflutren protein-type A microspheres injectable suspension. METHODS: This study used the largest hospital service-level database in the U.S. All adult patients undergoing in-patient echocardiography between January 2003 and October 2005 were identified (n = 2,588,722, of which 22,499 received perflutren protein-type A microspheres injectable suspension). Of the 22,499 contrast echocardiography patients, 2,900 had diagnoses meeting criteria for critical illness (heart failure, acute myocardial infarction, arrhythmia, respiratory failure, pulmonary embolism, emphysema, and pulmonary hypertension). To control for the differences between the contrast and noncontrast patients, we used propensity score matching. Variables used in the construction of the propensity score included comorbidities, demographic factors, hospital-specific factors, level of care, and mechanical ventilation status. Patients receiving contrast echocardiography were matched to 4 control patients who received noncontrast echocardiography. Conditional logistic regression was used to estimate mortality effects. RESULTS: There were 167 deaths in the study among critically ill patients, 38 of 2,900 from the contrast group and 129 of 11,600 from the control group. The contrast agent was not associated with an increase in same-day mortality (odds ratio: 1.18; 95% confidence interval: 0.82 to 1.71; p = 0.37). Before matching, contrast patients showed greater morbidity than noncontrast patients (Deyo-Charlson comorbidity score 2.45 vs. 2.25, p < 0.0001). After propensity score matching, these differences were significantly reduced, showing that both groups were well balanced. CONCLUSIONS: There is no increase in mortality in critically ill patients undergoing echocardiography with the UCA compared with case-matched control patients.
机译:目的:比较在有或没有超声造影剂(UCA)的情况下接受超声心动图检查的危重住院患者的急性死亡率。背景:由于在服用含全氟醚的UCA后立即报告严重的心肺反应,FDA要求此类药物包括黑素全蛋白A型微球可注射混悬液,应发出黑盒安全警告。方法:本研究使用了美国最大的医院服务水平数据库。确定了2003年1月至2005年10月之间所有接受住院超声心动图检查的成年患者(n = 2,588,722,其中22,499人接受了全氟哌啶蛋白A型微球注射悬浮液治疗)。在22499例造影超声心动图患者中,有2900例诊断符合危重疾病标准(心力衰竭,急性心肌梗塞,心律不齐,呼吸衰竭,肺栓塞,肺气肿和肺动脉高压)。为了控制对比患者和非对比患者之间的差异,我们使用了倾向得分匹配。倾向评分构建中使用的变量包括合并症,人口统计学因素,医院特定因素,护理水平和机械通气状态。接受造影超声心动图检查的患者与接受非造影超声心动图检查的4例对照患者相匹配。条件对数回归用于估计死亡率影响。结果:本研究中危重患者死亡167例,对照组为2900例中的38例,对照组为11600例中的129例。造影剂与当天死亡率的增加无关(赔率:1.18; 95%置信区间:0.82至1.71; p = 0.37)。在匹配之前,对比患者的发病率要高于非对比患者(Deyo-Charlson合并症得分2.45 vs. 2.25,p <0.0001)。倾向得分匹配后,这些差异显着降低,表明两组都很好地保持了平衡。结论:与病例匹配的对照患者相比,接受UCA超声心动图检查的危重患者死亡率没有增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号